sur Topadur Pharma AG
Topadur Pharma Appoints New CEO to Drive Growth
Topadur Pharma AG, a Swiss biotechnology company, announces the appointment of Dr. Matthias Schäfer as Chief Executive Officer. This decision marks a pivotal moment as the company progresses its clinical pipeline. Dr. Schäfer, previously Chief Innovation Officer at Topadur, brings over 20 years of life sciences experience. His leadership aims to enhance the company's momentum as it seeks commercialization.
Founder Dr. Reto Naef transitions to Senior Scientific Advisor, maintaining strategic guidance. Topadur's key asset, TOP-N53, targets digital ulcers in systemic sclerosis and has achieved Phase 2a clinical development and Orphan Drug Designation by FDA and EMA. This asset addresses major global health challenges, including diabetic foot ulcers.
Future priorities include advancing TOP-M119 for alopecia treatment. The firm's DualTOP® platform supports innovative therapeutic developments, reinforcing Topadur's expansion in skin rejuvenation and oncology.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Topadur Pharma AG